佛跳墙专业版3官网
Leveraging a broad innovation network, our venture team identifies transformational healthcare ideas at leading research labs and medical centers, then works with scientific founders to quickly hit development milestones.
佛跳墙专业版3官网
We’re not your typical healthcare VC firm. Through our strategic investments and partnerships, ShangPharma Innovation is focused on filling the critical investment gap that exists for earliest-stage therapeutic breakthroughs.
佛跳墙专业版3官网
佛跳墙专业版3官网
佛跳墙专业版3官网
/in Media, Media Coverage, 手机app加速器 /by shawnCAMBRIDGE, England and HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2024 /PRNewswire/ — Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announce the in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma. Under the agreement, Artios has exclusive rights to research, develop, manufacture and commercialize […]